NDAORALTABLET, CHEWABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
CHEWTADZY (tadalafil) by Fosun Pharma is muscle. Approved for erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHEWTADZY is a chewable tablet formulation of tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor approved in June 2024 by Fosun Pharma. It treats erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension by inhibiting PDE5 to increase cGMP levels and promote smooth muscle relaxation and blood flow. The chewable formulation offers a differentiated dosage form versus existing oral tablets.
Growth
Early-stage launch product in growth phase with moderate competitive pressure (30/100); team expansion likely as market penetration develops.
Mechanism of Action
muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of…
Worked on CHEWTADZY at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.